Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Uterine Cervical Dysplasia 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Thyroid Nodule 1Thyroid Diseases 1Stomach Neoplasms 1Papillomavirus Infections 1Pancreatic Neuroendocrine Tumors (pNET) 1Oropharyngeal Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Muscle-invasive Bladder Cancer 1Mouth Neoplasms 1Melanoma 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Acquired Immunodeficiency Syndrome 1

Interventions

Gemcitabine 6Radiotherapy 4Mitomycin 3Epirubicin 2toripalimab 1tislelizumab 1pirarubicin 1hydroxycamptothecinum 1Watchful Waiting 1Maintenance 1Injections 1Docetaxel 1BCG Vaccine 1Anesthesia, Spinal 1Anesthesia, General 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Non-Muscle Invasive Bladder Neoplasms × Watchful Waiting × Clear all
NCT07625527 2026-06-04

Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?

Tianjin Medical University Second Hospital

Phase 2 Not yet recruiting
120 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡